RXK3.F SELLAS Life Sciences Group Inc

Healthcare Biotechnology Frankfurt Exchange
8.66 EUR
Close of Nov 13, 2026
1.20 14.95
Market cap
EUR 1.75B
P/E
-
P/B
12.48x
ROE
-26.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is RXK3.F undervalued?

Graham number

The Graham number of SELLAS Life Sciences Group Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SELLAS Life Sciences Group Inc fundamental analysis

No fundamental analysis for SELLAS Life Sciences Group Inc yet.

SELLAS Life Sciences Group Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SELLAS Life Sciences Group Inc

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to eval…

Full company profile